Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER Stock Report

Market Cap: Ft1.7t

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Valuation

Is RICHTER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RICHTER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RICHTER (HUF9265) is trading below our estimate of fair value (HUF21918.67)

Significantly Below Fair Value: RICHTER is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RICHTER?

Other financial metrics that can be useful for relative valuation.

RICHTER key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA6.3x
PEG Ratio0.6x

Price to Earnings Ratio vs Peers

How does RICHTER's PE Ratio compare to its peers?

The above table shows the PE ratio for RICHTER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average18.3x
600566 Hubei Jumpcan Pharmaceutical
13.4x10.0%CN¥33.7b
002603 Shijiazhuang Yiling Pharmaceutical
12.5x6.8%CN¥33.8b
ROVI Laboratorios Farmaceuticos Rovi
24.5x13.1%€4.2b
KLBF Kalbe Farma
22.8x10.7%Rp67.5t
RICHTER Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
10.7x16.9%Ft1.7t

Price-To-Earnings vs Peers: RICHTER is good value based on its Price-To-Earnings Ratio (10.7x) compared to the peer average (18.3x).


Price to Earnings Ratio vs Industry

How does RICHTER's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a13.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: RICHTER is good value based on its Price-To-Earnings Ratio (10.7x) compared to the European Pharmaceuticals industry average (24.4x).


Price to Earnings Ratio vs Fair Ratio

What is RICHTER's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RICHTER PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.7x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RICHTER's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RICHTER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentFt9,265.00
Ft11,515.56
+24.3%
10.4%Ft13,400.00Ft9,435.00n/a9
Mar ’25Ft9,625.00
Ft11,330.56
+17.7%
10.9%Ft13,400.00Ft9,435.00n/a9
Feb ’25Ft9,765.00
Ft10,903.89
+11.7%
10.2%Ft12,990.00Ft9,435.00n/a9
Jan ’25Ft8,750.00
Ft10,631.11
+21.5%
8.0%Ft12,000.00Ft9,435.00n/a9
Dec ’24Ft8,820.00
Ft10,631.11
+20.5%
8.0%Ft12,000.00Ft9,435.00n/a9
Nov ’24Ft8,475.00
Ft10,542.22
+24.4%
9.1%Ft12,600.00Ft9,435.00n/a9
Oct ’24Ft8,915.00
Ft10,426.67
+17.0%
10.0%Ft12,600.00Ft9,260.00n/a9
Sep ’24Ft8,965.00
Ft10,426.67
+16.3%
10.0%Ft12,600.00Ft9,260.00n/a9
Aug ’24Ft8,935.00
Ft10,203.33
+14.2%
11.2%Ft12,600.00Ft8,900.00n/a9
Jul ’24Ft8,420.00
Ft10,203.33
+21.2%
11.2%Ft12,600.00Ft8,900.00n/a9
Jun ’24Ft8,600.00
Ft10,203.33
+18.6%
11.2%Ft12,600.00Ft8,900.00n/a9
May ’24Ft8,170.00
Ft10,123.33
+23.9%
11.8%Ft12,600.00Ft8,600.00n/a9
Apr ’24Ft7,325.00
Ft10,166.25
+38.8%
13.0%Ft12,800.00Ft8,600.00n/a8
Mar ’24Ft7,585.00
Ft10,966.25
+44.6%
14.4%Ft14,000.00Ft9,260.00Ft9,625.008
Feb ’24Ft8,145.00
Ft10,853.75
+33.3%
15.4%Ft14,000.00Ft8,820.00Ft9,765.008
Jan ’24Ft8,300.00
Ft10,834.75
+30.5%
16.9%Ft14,000.00Ft8,783.00Ft8,750.008
Dec ’23Ft8,500.00
Ft10,482.57
+23.3%
16.0%Ft14,000.00Ft8,783.00Ft8,820.007
Nov ’23Ft8,180.00
Ft9,846.86
+20.4%
9.8%Ft11,700.00Ft8,783.00Ft8,475.007
Oct ’23Ft7,400.00
Ft10,024.17
+35.5%
9.2%Ft11,700.00Ft8,820.00Ft8,915.006
Sep ’23Ft7,965.00
Ft9,494.71
+19.2%
17.9%Ft11,700.00Ft5,788.00Ft8,965.007
Aug ’23Ft8,100.00
Ft8,876.86
+9.6%
14.6%Ft9,900.00Ft5,788.00Ft8,935.007
Jul ’23Ft6,940.00
Ft8,676.86
+25.0%
15.5%Ft9,900.00Ft5,788.00Ft8,420.007
Jun ’23Ft7,300.00
Ft8,719.71
+19.4%
15.6%Ft9,900.00Ft5,788.00Ft8,600.007
May ’23Ft7,150.00
Ft8,949.13
+25.2%
15.5%Ft10,450.00Ft5,788.00Ft8,170.008
Apr ’23Ft7,180.00
Ft8,949.13
+24.6%
15.5%Ft10,450.00Ft5,788.00Ft7,325.008
Mar ’23Ft6,585.00
Ft9,541.14
+44.9%
17.4%Ft11,000.00Ft5,788.00Ft7,585.007

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.